Interview With Daniel Carcillo, Natalie Ginsberg, Olivia Mannix & Klee Irwin

This week on the Psychedelic Spotlight podcast, we provide a recap of the inaugural Benzinga Psychedelic Capital Conference which took place in Fontainebleau Miami Beach on April 19, 2022. This conference was the gathering of major psychedelics industry leaders and investors, and our Director of Video Production Matthew Dunehoo had the opportunity to attend and touch base with industry movers and shakers Daniel Carcillo from Wesana Health, Natalie Ginsberg from MAPS, Olivia Mannix from Felicity Pharma, and Klee Irwin from Irwin Naturals.

Benzinga Psychedelic Capital Conference Recap with MAPS, Wesana, Felicity Pharma and Irwin Naturals

Psychedelic Spotlight

Interview With Lauren Taus

June 30, 2021June 2, 2024 Listen, Podcasts

In this episode of the Psychedelic Spotlight podcast we speak with Lauren Taus who is the Founder of INBodied Life, who’s focus is on integrating modern science and ancient wisdom to support transformation.

Interview With Anthony Tennyson

July 9, 2021June 2, 2024 Listen, Podcasts

We speak with Anthony Tennyson, CEO of Awakn Life Sciences, a biotechnology company with clinical operations developing and delivering psychedelic medicine to treat addiction.

Psychedelic Spotlight Interview with Pierre Bouchard

September 15, 2021June 2, 2024 Listen, Psychedelic Spotlight Videos

In this episode of the Psychedelic Spotlight podcast, we speak…

Measuring Psychedelic Integration to Track Success

March 13, 2023June 2, 2024 Learn, Research

Integration is an essential part of psychedelic therapy, and now there is a new scale for measuring psychedelic integration.

Fixing Your Nervous System Dysregulation May Fix Your Anxiety and Depression with John Wood

April 20, 2023June 2, 2024 Listen, Podcasts

In this episode, Sacha Hebbert and John Wood dive into a cautionary tale about the darker side of the psychedelic industry, where cults, and snake oil svengalis pray on open seekers all the time.

Is Compass Pathways a GOOD INVESTMENT? (CMPS stock analysis)

January 10, 2021June 2, 2024 Listen, Videos

In this episode, we take a deep dive into Compass Pathways (CMPS), a psychedelic-medicines company aiming to treat depression with psilocybin.

To understand Compass Pathways (CMPS ), as a company and as an investment, you have to study 5 things:

What problem is Compass Pathways trying to solve?
CMPS’ clinical trial, treating depression with psilocybin
The founders and leaders of Compass Pathways
Compass’ Financials
Is CMPS stock a good investment for a retail investor?

As the psychedelic stocks sector takes off, Compass Pathways, alongside MindMed (MMED / MMEDF), looks poised to lead the pack. No other psychedelic-medicines company is as advanced in a clinical trial as is Compass Pathways (CMPS). CMPS has a phase 2b trial to test the effectiveness of psilocybin in treating Treatment-Resistant Depression could be game changing, and make for a great investment opportunity.
Let me know in the comments what you guys think. Is Compass Pathways a GOOD INVESTMENT? Will the CMPS stock skyrocket in 2021?

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

Resources:
https://compasspathways.com/

https://www.webmd.com/depression/understanding-depression-basics#1

https://www.psychiatry.org/patients-families/depression/what-is-depression

https://www.nimh.nih.gov/health/statistics/major-depression.shtml

https://www.webmd.com/depression/guide/depression-treatment-options#1

https://www.ncbi.nlm.nih.gov/books/NBK361016/#:~:text=Inotherwordsantidepressantsare,foundtobeequallyeffective

https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-019-2222-4#:~:text=Treatmentresistantdepression(TRD),MDDpatientpopulation1

https://www.beckleyfoundation.org/psilocybin-for-depression-2

https://www.hopkinsmedicine.org/news/newsroom/news-releases/psychedelic-treatment-with-psilocybin-relieves-major-depression-study-shows

https://compasspathways.com/our-research/psilocybin-therapy/about-psilocybin-therapy/#from-subnav

https://psychedelicreview.com/person/ekaterina-malievskaia/

https://compasspathways.com/team-member/george-goldsmith/
https://compasspathways.com/team-member/lars-christian-wilde/

https://www.reuters.com/article/us-compass-pathways-ipo/peter-thiel-backed-compass-pathways-files-for-u-s-ipo-idUSKBN25O31T

https://www.globenewswire.com/news-release/2019/05/15/1825506/0/en/Anxiety-Disorder-and-Depression-Treatment-Market-To-Reach-USD-18-90-Billion-By-2026-Reports-And-Data.html

https://www.treehugger.com/facts-about-magic-mushrooms-4868810
https://psychedelicreview.com/person/ekaterina-malievskaia/

#CompassPathways #CMPS #PsychedelicStocks #MindMed #MMED #MMEDF #PsychedelicStocks #ThePsychedelicInvestor